Article
Severe exacerbation of chronic hepatitis B after emergence of lamivudine resistance in a cirrhotic patient: immediate switch to adefovir dipivoxil appears to be indicated.
Zeitschrift fur Gastroenterologie - 1 Jan 2004
Wiegand J, Tischendorf J J, Nashan B, Klempnauer J, Flemming P, Niemann P, Rohde P, Manns M P, Trautwein C, Tillmann H L
Abstract excerpt
INTRODUCTION: Lamivudine is a treatment option for the therapy of chronic hepatitis B with an excellent safety profile. Unfortunately, viral resistance to lamivudine is common in the course of therapy. The lamivudine resistant mutants are usually less pathogenic than the wild type, but development of viral resistance can also lead to acute exacerbation of the underlying hepatitis. The recently FDA approved...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.